Id: acc1552
Group: 2sens
Protein: ERBB4
Gene Symbol: ERBB4
Protein Id: Q15303
Protein Name: ERBB4_HUMAN
PTM: phosphorylation
Site: unclear
Site Sequence:
Disease Category: Cancer
Disease: Ovarian Cancer
Disease Subtype:
Disease Cellline: SK-OV-3
Disease Info:
Drug: Y-142
Drug Info: -
Effect: modulate
Effect Info: "Y-142 can also neutralize the phosphorylation of epidermal growth factor receptor and ERBB4 induced by HB-EGF, and inhibit the proliferation of cancer cells and endothelial cells induced by HB-EGF."
Note:
Score: 4.0
Pubmed(PMID): 23251664
Sentence Index:
Sentence:

Sequence & Structure:

MKPATGLWVWVSLLVAAGTVQPSDSQSVCAGTENKLSSLSDLEQQYRALRKYYENCEVVMGNLEITSIEHNRDLSFLRSVREVTGYVLVALNQFRYLPLENLRIIRGTKLYEDRYALAIFLNYRKDGNFGLQELGLKNLTEILNGGVYVDQNKFLCYADTIHWQDIVRNPWPSNLTLVSTNGSSGCGRCHKSCTGRCWGPTENHCQTLTRTVCAEQCDGRCYGPYVSDCCHRECAGGCSGPKDTDCFACMNFNDSGACVTQCPQTFVYNPTTFQLEHNFNAKYTYGAFCVKKCPHNFVVDSSSCVRACPSSKMEVEENGIKMCKPCTDICPKACDGIGTGSLMSAQTVDSSNIDKFINCTKINGNLIFLVTGIHGDPYNAIEAIDPEKLNVFRTVREITGFLNIQSWPPNMTDFSVFSNLVTIGGRVLYSGLSLLILKQQGITSLQFQSLKEISAGNIYITDNSNLCYYHTINWTTLFSTINQRIVIRDNRKAENCTAEGMVCNHLCSSDGCWGPGPDQCLSCRRFSRGRICIESCNLYDGEFREFENGSICVECDPQCEKMEDGLLTCHGPGPDNCTKCSHFKDGPNCVEKCPDGLQGANSFIFKYADPDRECHPCHPNCTQGCNGPTSHDCIYYPWTGHSTLPQHARTPLIAAGVIGGLFILVIVGLTFAVYVRRKSIKKKRALRRFLETELVEPLTPSGTAPNQAQLRILKETELKRVKVLGSGAFGTVYKGIWVPEGETVKIPVAIKILNETTGPKANVEFMDEALIMASMDHPHLVRLLGVCLSPTIQLVTQLMPHGCLLEYVHEHKDNIGSQLLLNWCVQIAKGMMYLEERRLVHRDLAARNVLVKSPNHVKITDFGLARLLEGDEKEYNADGGKMPIKWMALECIHYRKFTHQSDVWSYGVTIWELMTFGGKPYDGIPTREIPDLLEKGERLPQPPICTIDVYMVMVKCWMIDADSRPKFKELAAEFSRMARDPQRYLVIQGDDRMKLPSPNDSKFFQNLLDEEDLEDMMDAEEYLVPQAFNIPPPIYTSRARIDSNRSEIGHSPPPAYTPMSGNQFVYRDGGFAAEQGVSVPYRAPTSTIPEAPVAQGATAEIFDDSCCNGTLRKPVAPHVQEDSSTQRYSADPTVFAPERSPRGELDEEGYMTPMRDKPKQEYLNPVEENPFVSRRKNGDLQALDNPEYHNASNGPPKAEDEYVNEPLYLNTFANTLGKAEYLKNNILSMPEKAKKAFDNPDYWNHSLPPRSTLQHPDYLQEYSTKYFYKQNGRIRPIVAENPEYLSEFSLKPGTVLPPPPYRHRNTVV

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target Drug name MOA Phase Status Disease Source
ERBB4 NERATINIB MALEATE Receptor protein-tyrosine kinase erbB-4 inhibitor 4 - breast carcinoma FDA
ERBB4 DACOMITINIB Receptor protein-tyrosine kinase erbB-4 inhibitor 4 - neoplasm ATC
ERBB4 VANDETANIB Epidermal growth factor receptor inhibitor 4 - neoplasm ATC
ERBB4 VANDETANIB Epidermal growth factor receptor inhibitor 4 - thyroid carcinoma DailyMed
ERBB4 DACOMITINIB Receptor protein-tyrosine kinase erbB-4 inhibitor 4 - non-small cell lung carcinoma EMA
FDA
ERBB4 AFATINIB DIMALEATE Receptor protein-tyrosine kinase erbB-4 inhibitor 4 - non-small cell lung carcinoma DailyMed
ERBB4 AFATINIB DIMALEATE Receptor protein-tyrosine kinase erbB-4 inhibitor 4 Not yet recruiting non-small cell lung carcinoma ClinicalTrials
ERBB4 VANDETANIB Epidermal growth factor receptor inhibitor 4 - thyroid neoplasm EMA
ERBB4 VANDETANIB Epidermal growth factor receptor inhibitor 4 Active, not recruiting thyroid cancer ClinicalTrials
ERBB4 NERATINIB MALEATE Receptor protein-tyrosine kinase erbB-4 inhibitor 4 - breast cancer DailyMed
ERBB4 VANDETANIB Epidermal growth factor receptor inhibitor 4 - medullary thyroid gland carcinoma DailyMed
ERBB4 AFATINIB Receptor protein-tyrosine kinase erbB-4 inhibitor 3 Completed head and neck squamous cell carcinoma ClinicalTrials
ERBB4 AFATINIB Receptor protein-tyrosine kinase erbB-4 inhibitor 3 - neoplasm ATC
ERBB4 NERATINIB Receptor protein-tyrosine kinase erbB-4 inhibitor 3 - neoplasm ATC
ERBB4 AFATINIB Receptor protein-tyrosine kinase erbB-4 inhibitor 3 Completed non-small cell lung carcinoma ClinicalTrials
ClinicalTrials
ClinicalTrials
ClinicalTrials
ClinicalTrials
ClinicalTrials
ClinicalTrials
ERBB4 VANDETANIB Epidermal growth factor receptor inhibitor 3 Completed non-small cell lung carcinoma ClinicalTrials
ClinicalTrials
ClinicalTrials
ClinicalTrials
ERBB4 DACOMITINIB ANHYDROUS Receptor protein-tyrosine kinase erbB-4 inhibitor 3 Completed non-small cell lung carcinoma ClinicalTrials
ClinicalTrials
ERBB4 POZIOTINIB Epidermal growth factor receptor inhibitor 3 Suspended non-small cell lung carcinoma ClinicalTrials
ERBB4 AFATINIB Receptor protein-tyrosine kinase erbB-4 inhibitor 3 Completed breast neoplasm ClinicalTrials
ERBB4 NERATINIB Receptor protein-tyrosine kinase erbB-4 inhibitor 3 Recruiting biliary tract neoplasm ClinicalTrials
ERBB4 AFATINIB Receptor protein-tyrosine kinase erbB-4 inhibitor 3 Active, not recruiting upper aerodigestive tract neoplasm ClinicalTrials
ERBB4 AFATINIB Receptor protein-tyrosine kinase erbB-4 inhibitor 3 Terminated upper aerodigestive tract neoplasm ClinicalTrials
ClinicalTrials
ERBB4 VANDETANIB Epidermal growth factor receptor inhibitor 3 Active, not recruiting thyroid cancer ClinicalTrials
ERBB4 VANDETANIB Epidermal growth factor receptor inhibitor 3 Completed thyroid cancer ClinicalTrials
ERBB4 NERATINIB Receptor protein-tyrosine kinase erbB-4 inhibitor 3 Completed breast cancer ClinicalTrials
ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No intensity data of this site,
show all other sites!

ERBB4-Ser1124
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM -0.707
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC 0.707
ERBB4-Ser726
Cancer Intensity
BRCA
COAD
HGSC 1.005
ccRCC
GBM -0.995
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC -0.01
ERBB4-Thr699
Cancer Intensity
BRCA
COAD
HGSC -1.155
ccRCC
GBM 0.595
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC 0.56

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
- - P Breast cancer/tumor/carcinoma Phosphorylation 11389077

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: